hFCER1A(2)/hIGHE

Nomenclature

C57BL/6JSmo-Fcer1atm1(hFCER1A)Ighetm(hIGHE)Smoc

Cat. NO.

NM-XA-250157

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
Ighe

Model Description

The hFCER1A(2) (NM-HU-241758) was crossed with hIGHE(NM-HU-220512) to generate hFCER1A(2)/hIGHE mice.

Validation Data

image.png

Fig.1 Detection of human IgHE expression in serum by ELISA. 

Serum was collected from wild-type C57BL/6 mice (WT) and homozygous hFCER1A/hIGHE mice (HO/HO) (n=2, female, 6 weeks old). Protein expression level of human IGHE was analyzed by ELISA. 

The human IgE Elisa kit cross-reacted with mouse IgE and humanized IgE.

image.png

Fig.2 Detection of hFCER1A expression on CD117+ cells in peritoneal lavage fluid of WT C57BL/6 mice and hFCER1A/hIGHE mice by FACS. Leukocytes were collected from wild-type (WT) C57BL/6 mice (male, 9 weeks old) and homozygous(HO) hFCGR1A mice (male, 9-10 weeks old), and analyzed by flow cytometry with anti-mFCER1A and anti-hFCER1A. hFCER1A was exclusively detectable in hFCER1A/hIGHE humanized mice but not in wild-type mice. hFCER1A was exclusively detectable on CD117+ cells in hFCER1A/hIGHE humanized mice, whereas mFCER1A was exclusively detectable on CD117+ cells in wild-type C57BL/6 mice.

f5a5f15b-763a-4253-8079-c77393df4fc5.png

Fig.3 Effects of Omalizumab on OVA-induced ASA. hFCER1A(2)/hIGHE mice (HO/HO) were immunized with OVA/Al(OH)3 on day 0 and day 7, and challenged with OVA on day 14. Omalizumab was injected 3 hours before the challenge on day 14. The rectal temperature of the mice was recorded from 0 to 90 minutes after the challenge. The results showed that Omalizumab had an inhibitory effect on the decrease in rectal temperature caused by ASA modeling in hFCER1A(2)/hIGHE mice (HO/HO). 

Abbr. HO, homozygous; 


You may also like

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more